Access BNP II
BECKMAN COULTER, INC. · Decision date Oct 20, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on October 20, 2026 for Access BNP II, a 510(k) submitted by Beckman Coulter, Inc. of Chaska, Minnesota under K262597. The device is classified as a B-type natriuretic peptide test system under 21 CFR 862.1117, Class II, product code NBC, with Clinical Chemistry as the regulation medical specialty and review panel. The application was received July 27, 2026 and reviewed as a traditional 510(k) without third-party review; it was not a combination product and no predetermined change control plan was authorized.
SESE denotes clearance to market, not premarket approval. The available excerpts do not state the specific assay components, intended-use wording, or performance data supporting the determination, and the decision summary itself was not captured in the source excerpts. The FDA letter notes general controls obligations such as registration and listing, labeling, and good manufacturing practice, but the excerpted text is truncated. Any reading of clinical utility or labeling claims beyond the recorded classification would require the full decision documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Oct 20, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262597
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- BECKMAN COULTER, INC.
- Product code
- NBC
- Decision code
- SESE
- Decision date
- Oct 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, Natriuretic Peptide.
- Applicant
- BECKMAN COULTER, INC.
- Product code
- NBC
- FDA device class
- 2
FDA decision timeline
K262597 received
Application receipt date recorded by FDA.
K262597 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NBC
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Access NT-proBNPK262109 | BECKMAN COULTER, INC. | 510(k) clearance | Sep 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
BECKMAN COULTER, INC.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Chaska, MN
Sources and methodology
- Original FDA record: K262597
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records